Johnson & Johnson Reports Positive Trial Results for Experimental Cancer Drug
Johnson & Johnson (JNJ) reported positive clinical trial results showing durable responses in patients with advanced head and neck cancer treated with its experimental subcutaneous formulation of amivantamab. The data was presented at a medical conference, potentially supporting expanded use approval.
Tickers: $JNJ
Topics: clinical trials head and neck cancer pharmaceuticals